Laboratorio Reig Jofre Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Laboratorio Reig Jofre.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth | 13.7% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
Calculating The Fair Value Of Laboratorio Reig Jofre, S.A. (BME:RJF)
Jun 22These 4 Measures Indicate That Laboratorio Reig Jofre (BME:RJF) Is Using Debt Extensively
Feb 02This Analyst Just Downgraded Their Laboratorio Reig Jofre, S.A. (BME:RJF) EPS Forecasts
Mar 07We Think Laboratorio Reig Jofre (BME:RJF) Is Taking Some Risk With Its Debt
Mar 07Laboratorio Reig Jofre (BME:RJF) Seems To Use Debt Quite Sensibly
May 17The Laboratorio Reig Jofre (BME:RJF) Share Price Has Gained 146%, So Why Not Pay It Some Attention?
Mar 07Is Laboratorio Reig Jofre (BME:RJF) Using Too Much Debt?
Jan 14Laboratorio Reig Jofre (BME:RJF) Shareholders Booked A 47% Gain In The Last Year
Dec 05In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Laboratorio Reig Jofre has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2025 | 340 | 11 | N/A | N/A | N/A |
12/31/2024 | 339 | 10 | N/A | N/A | N/A |
9/30/2024 | 334 | 10 | N/A | N/A | N/A |
6/30/2024 | 334 | 9 | -3 | 16 | N/A |
3/31/2024 | 326 | 9 | N/A | N/A | N/A |
12/31/2023 | 318 | 9 | 6 | 19 | N/A |
9/30/2023 | 316 | 12 | N/A | N/A | N/A |
6/30/2023 | 298 | 10 | 6 | 18 | N/A |
3/31/2023 | 286 | 10 | N/A | N/A | N/A |
12/31/2022 | 274 | 8 | 5 | 16 | N/A |
9/30/2022 | 262 | 4 | N/A | N/A | N/A |
6/30/2022 | 256 | 5 | -6 | 5 | N/A |
3/31/2022 | 245 | 3 | N/A | N/A | N/A |
12/31/2021 | 240 | 5 | -5 | 14 | N/A |
9/30/2021 | 237 | 6 | N/A | N/A | N/A |
6/30/2021 | 234 | 5 | 9 | 22 | N/A |
3/31/2021 | 234 | 6 | N/A | N/A | N/A |
12/31/2020 | 234 | 6 | 7 | 19 | N/A |
9/30/2020 | 229 | 8 | N/A | N/A | N/A |
6/30/2020 | 229 | 6 | -15 | 14 | N/A |
3/31/2020 | 219 | 6 | N/A | N/A | N/A |
12/31/2019 | 206 | 5 | -19 | 12 | N/A |
9/30/2019 | 199 | 7 | N/A | N/A | N/A |
6/30/2019 | 188 | 9 | -10 | 16 | N/A |
3/31/2019 | 188 | 9 | N/A | N/A | N/A |
12/31/2018 | 185 | 9 | N/A | 15 | N/A |
9/30/2018 | 185 | 10 | N/A | N/A | N/A |
6/30/2018 | 179 | 9 | N/A | 14 | N/A |
3/31/2018 | 175 | 9 | N/A | N/A | N/A |
12/31/2017 | 172 | 9 | N/A | 21 | N/A |
9/30/2017 | 164 | 5 | N/A | N/A | N/A |
6/30/2017 | 164 | 7 | N/A | 8 | N/A |
3/31/2017 | 164 | 8 | N/A | N/A | N/A |
12/31/2016 | 161 | 8 | N/A | -1 | N/A |
9/30/2016 | 160 | 5 | N/A | N/A | N/A |
6/30/2016 | 159 | 5 | N/A | 8 | N/A |
3/31/2016 | 156 | 5 | N/A | N/A | N/A |
12/31/2015 | 157 | 9 | N/A | 13 | N/A |
12/31/2014 | 133 | 9 | N/A | -13 | N/A |
9/30/2014 | 122 | 9 | N/A | 12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if RJF's forecast earnings growth is above the savings rate (2.1%).
Earnings vs Market: Insufficient data to determine if RJF's earnings are forecast to grow faster than the Spanish market
High Growth Earnings: Insufficient data to determine if RJF's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if RJF's revenue is forecast to grow faster than the Spanish market.
High Growth Revenue: Insufficient data to determine if RJF's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RJF's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/06/12 18:11 |
End of Day Share Price | 2025/06/12 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Laboratorio Reig Jofre, S.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Francisco Ruiz | BNP Paribas Exane |
Luis Esteban Arribas | Lighthouse-IEAF Servicios de Analisis |